Skip To Main Content
Elizabeth Eaton on Muck Rack

Elizabeth Eaton

Verified
Seattle
As seen in: FirstWord Pharma, Color Research & Application, HuffPost, USA Today, Allrecipes, AZCentral | The Arizona Republic, The Daily Wildcat, Science News, BioRxiv, Arizona Daily Star, Religion News Service and
Writer and lover of cake. @wctdlive co-writer. Science, sustainability and food writing published in @FoodTank @BioCentury @ScienceNews @azcentral @TucsonStar
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Elizabeth

Contact Elizabeth, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA Panel To Review Grail’s Blood-based Cancer Test

|
By Elizabeth Eaton Verified
| Cyber Era
By Elizabeth S. Eaton Shares in Grail climbed close to 10 per cent on Friday after the liquid biopsy developer announced that an FDA advisory committee (adcom) will review the premarket approval (PMA) application for its multi-cancer early detection (MCED) Galleri test.
Open in Who Shared Issue with article?

Another of Pfizer's Seagen-sourced ADCs stumbles in the clinic

|
By Elizabeth Eaton Verified
| FirstWord Pharma Verified
With some analysts already questioning the value of Pfizer's $43-billion acquisition of Seagen and its antibody-drug conjugate (ADC) pipeline, a late-stage miss for one of the more promising candidates gained from the buyout, sigvotatug vedotin, may further cast doubt on the deal.
Open in Who Shared Issue with article?

Sanofi joins big pharma syndicate backing COUR's diabetes immunotherapy

|
By Elizabeth Eaton Verified
| FirstWord Pharma Verified
COUR Pharma has refilled its coffers in a $50-million series B that saw backing from several major drugmakers, including new investor Sanofi. The funds will be used to advance a potentially disease-modifying type 1 diabetes treatment designed using the biotech's nanoparticle technology.
Open in Who Shared Issue with article?
See all 2,319 licensed articles (2,320 Total)